DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute...
United States University Of California San Diego Jamese Brown Craig Mcclain Tarek Hassanein University Scholar At Of Louisville
Source: prnewswire.com